Mona Al Mukaddam, M.D., M.S.

faculty photo
Professor of Clinical Medicine (Endocrinology, Diabetes and Metabolism)
Department: Medicine

Contact information
3rd floor Penn Medicine University City
3737 Market Street
Philadelphia, PA 19104
Office: 215-662-9905
Education
BS
American University of Beirut, Lebanon, 2001.
MD
American University of Beirut, Lebanon, 2005.
MS
University of Pennsylvania, Institute of Translational Medicine and Therapeutics, 2013.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

Rare bone disease with expertise in Fibrodysplasia Ossificans Progressiva and hypophosphatasia. Metabolic bone and calcium disorders including osteoporosis, Paget's disease, hypo- and hyper-parathyroidism as well as bone diseases related to transplant, medications (example aromatase inhibitors and glucocorticoids) and iron overload.

Description of Research Expertise

Clinical research in Fibrodysplasia Ossificans Progressiva and hypophosphatasia.
Evaluation of osteoporosis and the effects of treatment/diseases on "bone quality" using high resolution imaging of bone (uMRI).

Selected Publications

Mona Al Mukaddam, Robert Pignolo, Edward Hsiao, Kelly Wentworth, Jad Sfeir, Staci Kallish, Deborah Wenkert, Fredrick Kaplan: Baseline Characteristics in Part 1 of the ongoing ANDECAL Study (ASH-FOP-201), a two-part Phase 2/3 Study of andecaliximab (anti-matrix metalloproteinase-9 mAb) in FOP. Oral presentation and poster at the FOP Drug Development Forum, Toronto August 2026.

Rahaf Sultan, Valerie Bai, Mona Al Mukaddam: Approach to Hypercalcemia in a Patient Taking Immune Checkpoint Inhibitor Therapy for Breast Cancer. Endocrine Society Annual Meeting, Chicago, IL June 2026.

Robert J Pignolo MD,  Caifeng Li, MD, PhD, Javier Bachiller-Corral, MD, Amanda McBride, MD,  Sue Moran, MSN, Qian Li, PhD,  Frederick S Kaplan, MD,  Mona Al Mukaddam, MD, MS: Zilurgisertib in Patients with Fibrodysplasia Ossificans Progressiva: Interim Results from the PROGRESS Study. Rapid Fire Oral Presentation and poster, Endocrine Society Annual Meeting June 2026.

Cassandra Crompton, Kassidy Baum, Michael Silvey, Mona Al Mukaddam: Comparison of Forteo® and PF708 teriparatide on improvements in bone mineral density JAPhA Pharmacotherapy Jan 2026.

Pignolo, Robert; Hsiao, Edward; Al Mukaddam, Mona; Baujat, Genevieve; Berglund, Staffan; Cheung, Angela; De Cunto, Carmen; Delai, Patricia; Haga, Nobuhiko ; Kannu, Peter; Mancilla, Edna; Marino, Rose; Shih, Fei; Strahs, Andrew; Kaplan, Frederick: Palovarotene Impact on Fibrodysplasia Ossificans Progressiva (FOP): Data from Month 48 of the Phase 3 MOVE Trial. JBMR plus 2026.

Alsayed Hasan M, Al Mukaddam M.: Burosumab use in fibroblast growth factor-23-mediated hypophosphatemia in McCune-Albright syndrome/fibrous dysplasia. JCEM Case Report 2026.

Robert J. Pignolo, Edward C. Hsiao, Mona Al Mukaddam, Monica Brova, Daniella Olonilua, Alan L. Shields, Timothy P. LaBranche, Cori Ann Sherwin, Elaine A. Boing, Negar Karimian, Oyinkan Solanke, Frederick S. Kaplan: Development of the Fibrodysplasia Ossificans Progressiva FLare EXperience Revised (FOP-FLEX-R©) Questionnaire: A patient-reported outcome measure. Bone 2026.

Scott C, Al Mukaddam M, Davis M, De Cunto CL, Hsiao EC, Pignolo RJ, Schwegler O, Artyomenko A, Croskery K, Hanman K, Sanchot B, Warnants E, Kaplan FS : Identifying global trends from case reports of fibrodysplasia ossificans progressiva: a scoping review. Ther Adv Musculoskelet Dis. Dec 2025.

Rahaf Sultan and Mona Al Mukaddam : "Bone Health and Prevalence of Low Bone Density/Osteoporosis in Gender Diverse Adults; A retrospective Study" ASBMR annual meeting Sept 2025.

Marah Alsayed Hasan, Mona Al Mukaddam : Burosumab Use in FGF-23 Mediated Hypophosphatemia in McCune Albright Syndrome. Poster Presentation at the Annual ASBMR meeting Sept 2025.

back to top
Last updated: 08/31/2026
The Trustees of the University of Pennsylvania